secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001683168-25-006171
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort
---------------------------------------------------------------------

- Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.
- PH-762 Phase 1b trial: 15 patients treated, 5 complete responses in cSCC; enrolling final 5th cohort.
- July 2025 warrant inducement raised ~$2.2M from exercise of existing warrants.
- R&D expenses $1.1M in Q2 2025, up from $0.9M YoY due to enrollment costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/0001683168-25-006171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-006171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer